<DOC>
	<DOCNO>NCT01115439</DOCNO>
	<brief_summary>In Afghanistan , study past 15 year show high degree Plasmodium falciparum resistance chloroquine ( 80 % ) recently increase degree resistance sulfadoxine-pyrimethamine monotherapy ( 12 % ) . In 2003 high failure rate chloroquine falciparum malaria lead national malaria treatment programme switch recommend first line drug treatment uncomplicated Plasmodium falciparum malaria artemisinin-based combination therapy ( ACT ) form Artesunate/Sulfadoxine-Pyrimethamine ( AS+SP ) . Second line drug treatment oral quinine ( 7 day ) . The aim study conduct ongoing monitor efficacy new combination P. falciparum group sentinel sit Afghanistan .</brief_summary>
	<brief_title>Artesunate+Sulfadoxine-Pyrimethamine Treatment Uncomplicated Falciparum Malaria</brief_title>
	<detailed_description>The objective study assess efficacy safety Artesunate/Sulfadoxine-Pyrimethamine ( AS+SP ) treatment uncomplicated P. falciparum infection Nangarhar , Kunar , Thakhar , Faryab malaria control center Afghanistan . This observational study . Patients receive recommend treatment P. falciparum malaria Afghanistan ( Nangarhar , Kunar , Thakhar , Faryab malaria control center ) . The participant febrile child six month age non-pregnant adult confirm uncomplicated P. falciparum infection . Patients treat AS+SP accord standard dosing regimen . Clinical parasitological parameter monitor 42-day follow-up period evaluate drug efficacy . The study conduct transmission season falciparum malaria , i.e . October 2009 January 2010 September-December , 2010 . Patients assess clinically via laboratory test , particularly focus whether recurrence recrudescence original infection reinfections . All bio-medical finding record specific patient case record form electronic form analyze data well final report send WHO-Afghanistan National malaria control program office action . The patient receive reasonable transportation cost follow-up visit well one insecticide treat bed-net end enrolment . The result study used assist Ministry Health Afghanistan assess current national treatment guideline uncomplicated P. falciparum malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Inclusion : Age six month . Monoinfection P. falciparum detect microscopy level 500150,000/µL asexual form Presence axillary tympanic temperature ≥ 37.5 °C oral rectal temperature ≥ 38 °C history fever past 24 h ; ability swallow oral medication ; ability willingness comply study protocol duration study comply study visit schedule ; Informed consent patient parent guardian case child 18 year age . Exclusion criterion : Presence general danger sign child age 5 year sign severe falciparum malaria accord definition World Health Organization ( WHO ) Mixed monoinfection another Plasmodium specie detect microscopy Presence severe malnutrition ( defined child whose growth standard 3 zscore , symmetrical oedema involve least foot midupper arm circumference &lt; 110 mm ) Presence febrile condition due disease malaria ( e.g . measles , acute low respiratory tract infection , severe diarrhoea dehydration ) know underlie chronic severe disease ( e.g . cardiac , renal hepatic disease , HIV/AIDS ) ; Regular medication , may interfere antimalarial pharmacokinetics ; History hypersensitivity reaction contraindication study medication ; Female 12 year age</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>falciparum malaria</keyword>
	<keyword>artemisinin combination treatment</keyword>
</DOC>